Themis Plans Trials for Dengue And Chikungunya Vaccines
By Cormac Sheridan
Friday, March 29, 2013
Themis Bioscience GmbH is planning to begin clinical trials of viral vaccine candidates to protect against Dengue virus and Chikungunya virus infections before year-end, following successful preclinical proof of concept studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.